The Technology Behind Theranos Could Still Disrupt The Entire Lab Business
Theranos is under a lot of heat these days. But even if the controversial biotech startup fails, it was right about one major thing: the blood testing experience is ripe for disruption.
Right now, people are wondering whether or not the blood testing company once valued at $10 billion is actually able to accurately run the innovative diagnostic tests that catapulted them to prominence.
Right now, people are wondering whether or not the blood testing company once valued at $10 billion is actually able to accurately run the innovative diagnostic tests that catapulted them to prominence.